Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 13, 2022 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 05, 2022 16:01 ET
|
Nabriva Therapeutics US, Inc
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial...
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
May 05, 2022 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
May 02, 2022 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
April 11, 2022 16:05 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
March 29, 2022 16:01 ET
|
Nabriva Therapeutics US, Inc
-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- ...
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
March 15, 2022 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...
Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2022 07:01 ET
|
Nabriva Therapeutics US, Inc
DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022
January 18, 2022 16:01 ET
|
Nabriva Therapeutics US, Inc
— Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged...
Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders
January 14, 2022 16:01 ET
|
Nabriva Therapeutics US, Inc
— Meeting to Reconvene on January 18, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company...